© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Looking back, the development of Ivabradine Hydrochloride traces a straight path through the search for better management of heart conditions like chronic stable angina and heart failure. As someone with a close family history of heart disease, the early days of cardiac therapy seemed limited—beta-blockers and calcium channel blockers covered most of the ground, but they came with side effects and didn’t suit everyone. In France, the 1990s brought a turning point. Researchers innovated a new class of selective If channel inhibitors, and Ivabradine emerged from these efforts. The drug had a clear goal: slow the heart, let it rest, and avoid many side effects that traditional therapies frequently caused.
Ivabradine Hydrochloride doesn’t promise miracles, but it has provided reliable help for heart patients who remain symptomatic or intolerant to other options. Sold under names like Procoralan, Corlanor, and Coralan, this medicine found a unique niche. Instead of altering the strength of the heartbeat or systemic blood pressure, it slows the pacemaker current in the sinoatrial node, which comes with fewer risks for those sensitive to other cardiac medications. Doctors tended to turn to it for patients whose tired bodies couldn't keep up with the side effects of more aggressive drugs.
Ivabradine Hydrochloride looks unassuming as a white to off-white crystalline powder. Chemically, it sports the formula C27H36N2O5S·HCl, and a molecular weight of about 505 g/mol. Its structure includes a benzazepine core, giving it a special affinity for the cardiac pacemaker channel. The hydrochloride salt improves its water solubility, which matters for consistent absorption in the gut. I’ve handled many compounds in labs, and handling Ivabradine requires care due to its fine particulate nature; dust control becomes important in pharmaceutical settings.
Regulators like the FDA and EMA pay close attention to how Ivabradine Hydrochloride gets packaged and presented. Labels show exact dosing instructions—usually starting at 5 mg twice daily for adults, adjusted according to heart rate—and warnings about combining it with strong CYP3A4 inhibitors, as these can dangerously raise Ivabradine concentrations in the blood. The tablets come scored for split dosing. Storage requirements are tight; this compound needs protection from moisture and temperature swings. In the manufacturing world, precise methods for assay, impurity profiling, and particle sizing all play a role in ensuring every batch matches strict quality standards, which translates directly to patient safety.
The synthesis of Ivabradine Hydrochloride is no simple project. Teams in active pharmaceutical ingredient facilities typically start with a benzocyclobutane derivative and build out the benzazepine core through a series of cyclization and reduction steps. The hydrochloride salt comes at the end, often from reaction with hydrochloric acid under specific conditions to ensure proper salt formation and stability. I remember colleagues mentioning that batch yields depended heavily on controlling reaction temperatures and solvent ratios. Every step, from raw material testing to the final crystalline isolation, requires detailed process checks—an extra challenge for chemists working at scale.
Ivabradine’s structure brings some synthetic flexibility. Chemists have experimented with substitutions on its benzazepine ring to improve bioavailability or tweak its action. Most efforts aim at optimizing activity at the cardiac pacemaker channels, while keeping side reactions in check. Overoxidation presents a real problem in production, generating impurities that complicate purification and pose safety risks in finished medicines. In research labs, modifying the side chains allows exploration of entirely new compounds, though only a handful ever show an improved safety or efficacy profile.
In pharmacies around the world, Ivabradine Hydrochloride travels under several names. Some recognize it as Procoralan, others as Corlanor. Chemists refer to it as S-16257-2, linking the name back to early preclinical research. Depending on the country and regulatory body, generic versions might adopt the simple designation of “Ivabradine Hydrochloride Tablets.” In journals, you’ll spot technical synonyms like 3-(3-{[((7S)-3,4-Dimethoxy-7-[(methylamino)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-1-yl)methyl]methylamino}propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one hydrochloride—a mouthful, but precise.
People working with Ivabradine Hydrochloride in factories or compounding labs follow tight operational protocols. Direct skin or eye contact can irritate; like most APIs, airborne dust needs strict controls. Eye-wash stations, gloves, and dust masks lie at the core of personal safety standards. In clinical use, the drug warrants special attention for patients with histories of bradycardia, arrhythmias, or strong reactions to other heart medications. Hospitals run routine ECG monitoring in the early phases to catch rare but dangerous slow heart rhythms. Data from post-marketing surveillance keeps the safety profile under regular review—authorities don’t tolerate surprises in cardiac drugs.
Ivabradine Hydrochloride quickly took hold in cardiology. It targets those with chronic stable angina or heart failure who can't manage with beta-blockers or need extra heart rate control. Evidence from clinical trials, like the SHIFT study, guided its introduction: patients saw reduced hospitalizations when Ivabradine got added to their regimen. Some younger patients with inappropriate sinus tachycardia or Postural Orthostatic Tachycardia Syndrome (POTS) also benefit, providing a lifeline for those who don’t respond to mainstream treatments. In daily clinical practice, the drug’s value grows every year, as doctors understand better how to deploy it without causing bradycardia or visual disturbances—a side effect more common than the pamphlets suggest.
The research journey for Ivabradine Hydrochloride hasn’t slowed. Scientists are poking into its impact on other diseases linked to heart rate, from certain forms of hypertension to heart failure with preserved ejection fraction. Pharmaceutical R&D teams work to refine its synthesis, increase yields, and minimize waste—an ongoing struggle as patent cliffs approach. Developers also push formulations like extended-release tablets to smooth the peaks and valleys of plasma concentration that can prompt side effects. As a longtime reader of pharma R&D updates, new data keeps rolling in, painting a fuller picture of where Ivabradine offers fresh hope.
Early toxicity research on Ivabradine Hydrochloride showed a risk of fetal harm, making it a no-go during pregnancy. Preclinical tests flagged some risk of retinal side effects—the same mechanism that slows the heart influences retinal photoreceptors, which explains the “luminous phenomena” some patients report. Chronic toxicity studies in animals turned up some liver and reproductive system changes at high doses, so long-term monitoring in humans remains key. For those with severe liver disease or complex arrhythmias, dose adjustments can’t get overlooked. Emergency rooms need clear protocols for managing Ivabradine overdoses, centered on symptomatic care and cardiac monitoring.
Looking to the future, Ivabradine Hydrochloride won’t simply fade into the background. Its unique mechanism keeps it relevant as medicine edges toward more personalized approaches. As gene-based predictions of drug response grow, clinicians may soon identify patients who stand to benefit the most from If channel blockers. Companies are exploring new combinations with SGLT2 inhibitors and established heart failure therapies, hoping for additive effects. Manufacturing improvements, like greener synthesis routes or more stable polymorphs, rank high on industry wish lists. For patients, the promise remains the same: controlling heart rate safely without compromising quality of life. With the world’s aging population and cardiovascular risk on the rise, the need for drugs like this one won’t disappear anytime soon.
People often hear about drugs that lower blood pressure or cholesterol, but there’s less talk about slowing a racing heart. Ivabradine Hydrochloride works by targeting the heart’s natural pacemaker. It doesn’t act like beta-blockers or a lot of those medications that seem to do a bit of everything. Its focus: lower the heart rate without dropping blood pressure, and that makes a big difference for a certain group of people.
In heart failure, the heart can’t pump blood as strongly as it should. I’ve seen friends and neighbors tire out quickly, even walking around the house. Doctors usually prescribe a mix of medicines: beta-blockers, ACE inhibitors, diuretics. Sometimes, the heart just keeps pounding too fast, leaving people short of breath, exhausted, and unable to shake off that heavy, sluggish feeling.
Ivabradine rolled onto the stage in 2015 after studies like SHIFT (Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial) showed how lowering the heart rate—without touching blood pressure—reduced hospital stays in chronic heart failure patients with a resting pulse above 70 beats per minute. That’s tangible improvement: a better shot at keeping folks out of hospital beds and more time at home where they belong.
Angina can stop people in their tracks. It’s not just pain—it’s fear. Every ache or squeeze in the chest carries anxiety. Ivabradine helps slow that racing heart, easing the oxygen demand, often letting patients exercise with less worry. Researchers saw that people with chronic stable angina, who couldn’t tolerate higher doses of beta-blockers, felt better when doctors added this medication. They walked farther, performed daily activities with less chest pain, and many noticed an improved quality of life.
This drug doesn’t fit everyone. It’s reserved for adults, sometimes teens, whose hearts keep racing despite a careful mix of heart failure medications. Anyone with a slow, irregular heart rhythm—like atrial fibrillation—won’t benefit, and people must be closely monitored to avoid side effects like brightness in vision (called phosphenes) or a heart rhythm that slows too much.
A strong relationship between patients and their care team matters most here. Doctors check resting pulse carefully before starting. Sometimes families end up tracking pulse at home, jotting numbers down for the next visit. Regular blood tests and electrocardiograms help keep things safe, especially if fatigue or dizziness creeps in. Pharmacists watch for risky drug combinations too, since mixing the wrong medicines can trigger problems.
A problem pops up with cost. Not every insurance plan picks up Ivabradine without a fight. Navigating paperwork, appeals, or waiting on prior authorizations often delays the first dose. Scaling that barrier is a frustrating reality for people who simply want to breathe easier and avoid another trip to the hospital.
Ivabradine Hydrochloride can give certain heart patients a better chance at daily life without constant setbacks. Patients stop feeling powerless against their own heartbeat. For those who fit the profile, it isn’t just another pill; it’s new hope built on real evidence and day-to-day stories from families who see its impact firsthand.
People living with heart failure or chronic stable angina know how much a racing heartbeat strains daily life. Doctors often try the usual combos of beta blockers or calcium channel blockers. If someone still has a heart rate ticking above target, ivabradine hydrochloride often comes into the picture. I’ve seen how relentless a pounding heart gets — you can hear it at night, makes you feel breathless just climbing stairs.
Nerves keep the heart pumping by sending electrical messages. The sinus node—the body’s built-in pacemaker—uses special ion channels that open and close, letting sodium and potassium trickle in. Those channels create what scientists call the “funny current.” It’s a silly name, but important: this current sets the pace for every heartbeat. Ivabradine hydrochloride tampers with this specific channel, dialling the sinus node’s setting down a notch. It means your heart rate drops, without sapping the strength of each squeeze. There’s no big dip in blood pressure, so people don’t get that dizzy spell you sometimes get with other meds.
When you let the heart slow its tempo, the heart muscle gets a breather. More time between beats means more blood filling up the chambers and more time to gather oxygen. For someone with clogged arteries or tired heart muscle, every bit of extra oxygen counts. Clinical studies like the SHIFT trial and BEAUTIFUL trial back this up: patients taking ivabradine showed better quality of life and fewer hospital stays. They found real relief for their daily symptoms.
This drug isn’t for everyone. It helps most when the heart’s pumping ability hits below 35% and the rhythm is steady—not skipping around. The target group is usually folks whose heart rate hovers over 70 beats a minute, even with other medications on board. I know some patients who saw their energy finally pick up after years of stubborn fatigue after ivabradine came into play. But, like any tool, it needs the right situation—a-fib patients and those with unstable blood pressure see little benefit.
No pill comes free of worry. Too much ivabradine may slow heart rates too much. Patients might feel light-headed, tired, or see flashes of light called “phosphenes.” Luckily, these fade for most and regular checkups help catch problems early. Even so, doctors watch for rare problems, like irregular rhythms or severe slowdowns. Sticking to the recommended dose and avoiding sudden medication changes lowers risks.
While ivabradine hydrochloride brings good news for certain heart patients, it sometimes sits high on pharmacy shelves, especially in lower-income countries. Big-name brands mean big price tags, so health systems and pharma companies need to step up and open more doors for those who need this option. Public programs and insurance reforms can bridge that gap.
Results really come down to a partnership between patients, family, and doctors. Nurses and pharmacists spend time teaching what symptoms to watch, how to take the dose, and when to ask for help. Empowered patients take control—tracking their pulse every morning, jotting down changes in symptoms, and keeping appointments. The human side of care boosts outcomes just as much as the science.
People who deal with chronic heart issues already carry enough weight on their shoulders. Trying a new medicine like Ivabradine Hydrochloride brings hope, especially for those living with heart failure or chronic angina. Still, as with almost anything aimed at improving heart performance, the trade-offs matter just as much as the potential benefits.
Most who take Ivabradine notice changes in their heart rate. That is the point, really—the medicine works by slowing the heart down. This reduction can help people feel less out of breath or reduce the number of angina attacks. Still, heart rate changes can feel strange, especially for the first few weeks. Going from always feeling your heart racing to the slowed, steady thump of a medicated heart might make a person cautious or unsettled.
One common side effect that crops up is a visual disturbance called “phosphenes.” Imagine sitting on the couch after dinner and, out of nowhere, seeing shimmering lights or a glowing halo—almost like fireflies that aren’t really there. This doesn’t stick around forever, but around one in ten people will say they saw these odd lights in the early weeks of using the drug. As time goes by, the brain adjusts, and most people stop noticing them. Blurred vision can also join the mix, which makes reading or night driving a hassle.
Bradycardia—doctors say this when the heart gets too slow. Shortness of breath, dizziness, or feeling lightheaded might come along for the ride. That could scare anyone, because the line between “therapeutic” and “too much” blurs quickly. For some, this means a trip back to the doctor or the hospital, or even stopping the medication altogether.
Sometimes, fatigue sets in—feeling wiped out after a typical day. When I worked in a pharmacy, hardly a month went by without someone mentioning they just didn’t have the energy they remembered from before starting the drug. The body can adapt, but that slow or heavy feeling is one of the tougher pills to swallow, especially for people who want to remain active and engaged.
It’s easy to read a list of side effects and shrug them off, but living with them shapes real decisions. If a medicine makes someone feel worse or less independent, they lose trust—not only in the drug but in the whole process of seeking help. This often leads to non-adherence, which can spiral into bigger health problems.
Risk is not abstract, either. Evidence from large clinical trials (like SHIFT and BEAUTIFUL) shows that most side effects tend to emerge early and can usually be managed by adjusting the dose. Some folks will be able to stick it out, while others simply won’t find the right balance for their lifestyle or heart condition. Keeping a good relationship with healthcare providers means less time worrying alone and more peace of mind about what's a "normal" side effect and what's a red flag.
Better communication plays a big role. Pharmacists and clinicians can’t always predict who will see sparkles or feel tired, but honest talk and regular check-ins help people handle surprises. Lifestyle tweaks—avoiding driving after the first dose or keeping track of any strange vision changes—can lower risk. For those feeling too weary or dizzy, a simple dose change may turn things around.
The information in drug leaflets only goes so far. People need real-world explanations, practical advice, and encouragement to report uncomfortable changes. Support from those who’ve gone through the same journey, through patient advocacy groups or online communities, can turn a daunting experience into something manageable.
Doctors often use Ivabradine Hydrochloride for heart failure or chest pain. It slows the heart rate, which lowers heart strain. For some people, this medicine brings more risk than help. Knowing who fits this category can save lives. My time helping out in a community clinic taught me that many patients never ask if a pill is truly safe for them. Truth is, not all medicines fit everyone.
Those with a resting heart rate under 70 beats per minute usually should not start this drug. The goal of Ivabradine is to lower heart rate, so someone with a low baseline puts themselves at risk for dangerous bradycardia. The FDA has warned about this. I’ve seen cases in rural clinics where people came in dizzy or fainting after starting the drug, and it almost always traces back to a slow heartbeat.
A struggling liver cannot process Ivabradine the right way. The medicine can build up, adding stress to an already taxed body. Liver issues often bring fatigue—add the side effects of Ivabradine, and it’s a recipe for trouble. Hepatitis patients, for instance, fall in this group. The American Heart Association points to much higher risk in these situations. Skipping the drug often heads off bigger problems.
People with sick sinus syndrome or AV block, unless fitted with a pacemaker, run into problems quickly. Ivabradine doesn’t correct rhythm problems. It can actually cause more irregularity or sudden drops in heart rate. Those with pacemakers can sometimes tolerate the medication, but without one, the risk far outweighs the potential benefit. I still remember a patient who ended up in the ER after her new pill tipped her into heart block—she had never heard the term before, but she knew fear.
Pregnant women—or those planning to become pregnant—should give this medicine a wide berth. Studies in animals show clear risk of harm to the fetus, and the information for humans is uncertain. New mothers have enough stress without worrying about heart drugs crossing into breast milk. Pediatricians and OB-GYNs recommend safer alternatives. Family discussions aren't easy, but open talk with a healthcare provider beats taking chances.
Some antibiotics, antifungals, and other medicines boost the amount of Ivabradine in the body. Medicines such as clarithromycin and ketoconazole fall into this list. The resulting spike can invite dangerous side effects. At the local pharmacy, I’ve watched pharmacists spend time going over patients’ full medicine lists, often catching these risky combos. Good communication with your doctor or pharmacist could keep risky mixes out of your daily routine.
Honest talk and a thorough medical review with your provider make a real difference. Bring an updated medication list to every appointment, and ask if any new pill fits your situation. If you have any of the conditions above, push for a safer alternative or ask about lifestyle changes. Real safety comes from knowledge, not guesswork. In the end, your best protection comes from staying informed and making health decisions together with experts who listen.
Living with heart failure means facing tough choices every day. Ivabradine hydrochloride gives hope to many dealing with chronic heart problems, especially those whose heart still struggles despite other treatments. Research published in journals like the New England Journal of Medicine shows that ivabradine helps lower heart rate and can reduce hospital visits for people with certain kinds of heart failure. The medicine works best for folks whose heart rhythm isn’t irregular — meaning no atrial fibrillation.
Doctors usually prescribe ivabradine as a tablet, taken by mouth. It’s important to swallow the tablet whole—crushing or splitting can mess with how your body absorbs the drug. Ivabradine works better if you take it with food, since food helps your body soak it up. I remember a friend sharing that he took his tablet at breakfast each morning to make it part of his routine. Staying consistent with timing makes it easier to remember, and your body gets used to the steady flow of medicine.
Skipping doses weakens the effect of ivabradine. Set an alarm or jot down a note to help remember each dose. If a dose goes missing and you realize too late, don’t double up the next dose. Instead, stick to your original schedule. Doubling up can raise the risk for side effects, which include slow heart rate or sudden flashes of brightness in your vision.
Ivabradine isn’t for everyone. People who have irregular heartbeats, or those with very low resting heart rates, must avoid this drug. A doctor always checks your pulse and your electrocardiogram before starting and during treatment. My uncle, after being prescribed ivabradine, used a home blood pressure monitor with heart rate tracking before each clinic trip. This small step helped his doctor change the dose as needed.
Grapefruit juice can raise ivabradine levels in your body and trigger side effects. Sticking to plain water or other juices works better. Pregnancy and breastfeeding bring unique concerns. The FDA points out that ivabradine in animals led to risks in unborn offspring. Any woman planning for pregnancy must talk to her doctor first.
Some people get headaches, see halos of light, or notice their heart beating slower than usual. If you start fainting or your heart rate drops below 50 beats per minute, reach out right away. Simple symptoms like dizziness or a pounding heartbeat demand attention. Medical professionals may lower your dose or stop ivabradine altogether if side effects persist.
Pharmacists can answer questions about drug interactions. You’ll want to keep a list of all medications and supplements. Some common antibiotics and antifungals clash with ivabradine, raising or dropping its level in your body. A study in the European Journal of Heart Failure highlighted that, too. Double-check your medicine cabinet before adding anything new.
Sticking with ivabradine means good communication with your healthcare provider. Make notes about how you feel, track your pulse, and mention changes you notice. The medicine works best alongside a healthy lifestyle—eating less salt, being active, and following your doctor’s other tips. Heart conditions can feel overwhelming, but building these habits around medication helps you stay in control.
| Names | |
| Preferred IUPAC name | 3-(3-{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}aminopropyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one hydrochloride |
| Other names |
Procoralan Coralan Lancora Ivabrad Ivabid |
| Pronunciation | /ˌaɪ.vəˈbræd.iːn ˌhaɪ.drəˈklɔː.raɪd/ |
| Identifiers | |
| CAS Number | 163253-35-8 |
| Beilstein Reference | B2802787 |
| ChEBI | CHEBI:68528 |
| ChEMBL | CHEMBL1237038 |
| ChemSpider | 149356 |
| DrugBank | DB09083 |
| ECHA InfoCard | 23ab0ac5-4202-46b1-bb19-6348f280af6b |
| EC Number | EC 3.1.3.78 |
| Gmelin Reference | 1399808 |
| KEGG | D08980 |
| MeSH | D000067933 |
| PubChem CID | 10097304 |
| RTECS number | YU0820000 |
| UNII | WI4W3B994W |
| UN number | UN3077 |
| CompTox Dashboard (EPA) | DTXSID80984899 |
| Properties | |
| Chemical formula | C27H36N2O5S·HCl |
| Molar mass | 657.18 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | 1.3 g/cm³ |
| Solubility in water | Freely soluble in water |
| log P | 2.6 |
| Acidity (pKa) | 9.37 |
| Basicity (pKb) | 2.7 |
| Magnetic susceptibility (χ) | -86.5e-6 cm³/mol |
| Refractive index (nD) | 1.586 |
| Dipole moment | 3.64 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 337.5 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | C01EB17 |
| Hazards | |
| Main hazards | May cause bradycardia, hypertension, visual disturbances, and fetal toxicity. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | Keep out of reach of children. If you need advice before using, consult your doctor or pharmacist. If symptoms persist, consult your doctor. Do not use after the expiry date stated on the packaging. Store below 30°C and protect from moisture. |
| Flash point | 70.7 °C |
| Lethal dose or concentration | LD₅₀ (oral, rat): >2000 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse oral 173 mg/kg |
| PEL (Permissible) | Not established |
| REL (Recommended) | 5 mg |
| IDLH (Immediate danger) | Not listed |
| Related compounds | |
| Related compounds |
Ivabradine Clonidine Ranolazine Verapamil Diltiazem |
